Trial Profile
A Phase I/II Trial of the PD-L1 Inhibitor, Durvalumab Plus CV301 in Combination With Maintenance Chemotherapy for Patients With Metastatic Colorectal or Pancreatic Adenocarcinoma
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 09 Feb 2024
Price :
$35
*
At a glance
- Drugs CV 301 (Primary) ; Durvalumab (Primary) ; Bevacizumab; Capecitabine
- Indications Adenocarcinoma; Colorectal cancer; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 04 Oct 2023 Status changed from active, no longer recruiting to discontinued.
- 14 Dec 2022 Primary endpoint has amended as time frame of (PFS) Colorectal Cancer changed to 24 months from 8.5 months, and (PFS) Pancreatic Cancer changed to 24 months from 4 months.
- 14 Dec 2022 Planned End Date changed from 1 Dec 2023 to 1 Aug 2023.